Articles from Unlearn AI

SAN FRANCISCO, CA AND NEWTON, MA / ACCESS Newswire / July 9, 2026 / Unlearn, a pioneer of AI-powered solutions for clinical development, today announced a collaboration with Acumen Pharmaceuticals (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). The collaboration will utilize Unlearn's AI-generated digital twins of trial participants in two of Acumen's AD clinical trials testing their AβO-specific antibody sabirnetug. Digital twins are comprehensive forecasts of an individual trial participant's clinical outcomes at all future timepoints across a given study, used to augment insights from existing trial data and strengthen clearer data-driven decision-making throughout clinical development.